Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GW Pharmaceuticals

- PMLiVE

NICE International relaunches, will offer advisory services

Meets growing demand from global health and social care organisations

- PMLiVE

NHS leader warns politicians not to ‘weaponise’ the health service

Top exec challenges main parties to provide credible solutions to big issues

- PMLiVE

NICE considering re-evaluation of quality of life assessment

Will address concerns around the watchdog's methodologies

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

- PMLiVE

Labour party plans to abolish NHS prescription charges

Comes amid increased focus on drug pricing in the US

- PMLiVE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

- PMLiVE

Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate

Judgement arrives ahead of European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links